Marshalltown City Council moves mall project forward
The mall would be re-named Shoppes at Marshalltown.
'I'm here in front of you with a grand vision for repurposing the mall,' said developer Glen Kitto. 'We can't attract national tenants without a brand new looking mall, so it's very important for us to get financing in order to make that happen.'
Iowa House sends PBM reform bill to governor's desk
Kitto estimated there would be 225 construction jobs to rebuild the mall. Once complete, the mall would employ around 250 people.
'What council will do tonight is simply discuss whether or not they want to pursue the writing of a development agreement,' said Carol Webb, Marshalltown City Administrator. 'The information that's contained in tonight's materials relates to major terms of the agreement such as what will, primarily the tax increment financing incentive.'
The council's vote was to move forward on terms, but did not approve the 20-year proposal, which under tax increment financing, would raise $7.2 million.
If things move forward, a store could open the doors in summer of 2026. So far, no retailers have signed on. Kitto said stores don't want it known what they are planning, but once one signs an agreement, others will follow.
Iowa News:
Marshalltown City Council moves mall project forward
Forecast: Who will see rain this week?
Iowa House sends PBM reform bill to governor's desk
Congressman Randy Feenstra files paperwork hinting he may run for governor
Pharmacy Benefit Manager reform bill to be debated
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
LucyRx Announces the Acquisition of CerpassRx, Enhancing Clinical Excellence and Expanding Access to Innovative Healthcare Solutions
This strategic move brings together industry leading service with modern, member-first prescription care. BETHESDA, Md., July 31, 2025--(BUSINESS WIRE)--LucyRx, a fast-scaling, next-generation pharmacy benefits manager (PBM) known for simplifying and improving access to prescription care, has signed a definitive agreement to bring CerpassRx into the LucyRx organization. The combination brings together CerpassRx's proven track record of exceptional service and cost containment with LucyRx's technology-driven clinical approach, all under a shared vision for smarter, more transparent prescription care. CerpassRx is a division of Nomi Health, a direct healthcare company. The transaction is subject to regulatory approvals and customary closing conditions and is expected to close in Q3 2025. By combining LucyRx's technology-driven clinical model with CerpassRx's service-first approach and cost containment expertise, this partnership creates a more impactful PBM solution - one that delivers smarter care, stronger savings, and a seamless experience for clients and members alike. Distinct Strengths. Shared Mission. Greater Value. LucyRx and CerpassRx bring distinct but highly complementary capabilities to this new chapter. LucyRx offers a proprietary Formulary Marketplace, a broad Connected Specialty Care Network that integrates leading health systems and specialty pharmacies, and personalized clinical guidance through its Care Guide model. Its clinical programs focused on high-impact areas like GLP-1 therapies and Women's Health deliver smarter, more proactive prescription care for members. CerpassRx excels in driving down prescription costs through proprietary cost containment strategies, flexible formulary design, and tailored clinical programs. With a high-touch service model, it delivers rapid implementation and measurable outcomes, earning a reputation for disrupting the traditional PBM model and building long-term trust with clients and members. Together, they form a national PBM platform that is performance-driven, clinically forward, and relentlessly focused on serving clients and members with clarity and accountability. A More Impactful Platform for Clients and Members Smarter Cost Containment: CerpassRx's proven cost-saving programs layered onto LucyRx's transparent pricing and formulary marketplace. Stronger Member Support: Integrated clinical teams, anchored by LucyRx's Care Guides and CerpassRx's personalized service culture. Scalable Innovation: LucyRx's AI-powered insights and infrastructure amplify CerpassRx's high-touch service, making care more personal at scale. "CerpassRx is a strong cultural and strategic fit for LucyRx," said David Blair, CEO of LucyRx. "We're combining two organizations who are relentlessly focused on performance, innovation and compassion, and continually raising the bar for what clients and members can expect from a PBM." "We're proud of the foundation CerpassRx has built, and we believe LucyRx is the right partner to take it even further," said Mark Newman, CEO and Co-Founder of Nomi Health. "This agreement reflects a shared vision for more transparent, tech-forward pharmacy care and we're confident it will create long-term value for clients, members, and the broader market." "Clients expect more from their PBM, and they should," said Susan Thomas, Chief Commercial Officer at LucyRx. "Together with CerpassRx, we expand both the reach and depth of our solutions. And we'll deliver an experience that is more personal, more affordable and more clinically impactful." "Joining LucyRx is a natural next step for our clients and our team," said John Nicolosi, PharmD, Interim President of CerpassRx. "Our shared values of clarity, accountability, and care make this a powerful combination. We're excited to extend our impact with the support of LucyRx's technology, scale, and clinical approach." What Clients and Members Can Expect There will be no changes to service, support, or operations as a result of this agreement. Clients and members will continue to receive the same high-quality care and responsiveness they've come to expect from both organizations. This move builds on LucyRx's momentum as a PBM committed to doing things differently, with an emphasis on clarity, clinical rigor, and measurable outcomes. As part of this agreement, Nomi Health and LucyRx will continue working together to support their shared clients and build on current partnership efforts to reduce pharmacy costs for both employers and their members, advancing a shared commitment to bring more transparency, innovation, and affordability to healthcare. About LucyRx LucyRx is fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its integrated specialty network, formulary marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 1,200 clients nationwide. This is prescription care, brilliantly reimagined. Learn more at About CerpassRx CerpassRx is a leading, full-service, pharmacy benefit manager based in Dallas-Fort Worth, Texas. Its services include prescription optimization, flexible formulary designs, personalized member support, and efficient mail and specialty pharmacy programs. Committed to driving efficiency and enhancing pharmacy benefit management, CerpassRx helps clients navigate the complexities of prescription care. For more information, visit About Nomi Health Nomi Health is rebuilding healthcare through its direct model. Founded in 2019, the company's integrated platform combines analytics, direct provider networks, and real-time payment solutions - providing the infrastructure that powers better healthcare. The company serves 4,000 customers nationwide, impacting 30 million lives and influencing over $200 billion in healthcare spend. Based in Orem, Utah, Nomi Health leads the movement to rebuild America's healthcare system. Learn more at View source version on Contacts Media Contact for LucyRx Tricia Bancroft516-241-6157press@ Strategic Partnerships Contact at LucyRx Alex Motola, Chief Business Officer and Head of M&Aamotola@ Media Contact for Nomi Health Rebeca Damico385-887-1641rebeca@ Sign in to access your portfolio
Business Journals
25-07-2025
- Business Journals
Waiting for pharmacy benefit manager reform from Washington? Here's what to do now.
If you're frustrated with your pharmacy benefit manager (PBM), join the club. A recent survey found that three-fifths of large-company benefit leaders said their PBM contracts were opaque, overly complicated, and contained clauses that profit the PBM at the expense of employers and patients. Thankfully, you're not stuck. Washington is working on PBM reform, one of the rare issues for which there is agreement between both parties in Congress and the Trump administration. Of course, consensus isn't always enough to create legislation, and any passed law will take time to come into force. A recently-enacted bill in Colorado addresses some of these issues, but will not apply to many large employer-sponsored plans. What follows is a guide to the problems with PBM contracts, the reform proposals, and two approaches to addressing the existing issues that don't require waiting on Washington: Finding a new generation of PBM committed to more transparency; and Negotiating a more transparent arrangement with your current PBM. The problem with large PBMs Pharmacy benefit managers were created to reduce employer costs, yet over time they have evolved in ways that often incentivize increases in plan sponsor and employee costs: Vertical Integration: Nearly 80% of the prescription market (which totaled $600 billion in 2023) is controlled by PBMs run by the three largest health insurance carriers: CVS Caremark (owns Aetna), OptumRX (owned by UnitedHealth Group), and Express Scripts (owned by Cigna). Spread pricing: PBMs charge employers more than they pay pharmacies for drugs, keeping the difference. Drug company rebates: These payments are often in return for PBMs steering business to their products and can include other undisclosed fees. Misaligned Incentives: By favoring their own specialty and mail-order (or retail) pharmacies, PBMs may be restricting competition and limiting their interest in negotiating the lowest pharmacy markups. A recent FTC study found that PBMs often charged employers a markup for specialty drugs distributed through their affiliated pharmacies of more than 100% — and sometimes more than 1,000%. Recently, the big PBMs have started joint ventures to manufacture their own generic and biosimilar drugs, creating another potential conflict. Secrecy: PBM common practices such as spread pricing, rebates, contractual gag clauses, price list manipulation and others have created an environment ripe with opaqueness and confusion for employers. The proposed legislation Congress has been looking closely at PBM reform for several years, and a detailed bipartisan bill was removed from last December's stop-gap budget after Elon Musk tweeted that it was too long. Leading committees are now working to pass something similar. Indeed, two bills that passed Committee last year were reintroduced: The Prescription Pricing for the People Act directs the Federal Trade Commission to complete its ongoing study of PBM practices. The Pharmacy Benefit Manager (PBM) Transparency Act bans spread pricing, incentivizes PBMs to pass 100% of the rebates they receive to plan sponsors, encourages transparency, and requires annual reporting by PBMs of their pricing, reimbursement, and rebate practices. Other proposals go further, including the Patients Before Monopolies Act, which would ban PBMs and insurance companies from owning a pharmacy. The states have been busy as well, increasing their oversight of PBM practices through new legislation and reporting requirements. Unintended consequences of all of this are a concern for consultants and employers looking to control costs. In Colorado, Governor Polis signed HB 25-1094 into law in May. Effective in 2027, this law will regulate how PBMs can earn income, how they structure their formulary, and how they reimburse unaffiliated versus PBM-affiliated pharmacies, among other changes. Unfortunately, this new law won't apply to many large employer-sponsored healthcare programs. So large employers in Colorado are still left to design their own pharmacy strategy. Switching to a transparency-oriented PBM In recent years, more employers have switched their pharmacy programs to a new crop of PBMs who are unaffiliated with large insurers—including Navitus Health Solutions, Rightway Rx, Capital Rx, and SmithRx—and offer a more transparent business model. The advantages Pass-through pricing: Employers get the full benefit of network discounts and rebates, and instead of spread pricing, they pay a disclosed administrative fee per prescription. Fewer conflicts: The independent PBMs are less likely to have pharmacy operations or other business interests that differ from those of employers. Transparent disclosures: Employers get access to granular information about the pricing of each prescription rather than the opaque summaries provided by the large PBMs. Aggressive cost management: The independent PBMs emphasize lower net cost options in their formularies and have strict prior authorization requirements for more expensive drugs. The disadvantages Negotiating intermediaries: Since the upstart PBMs are small, many band together by using rebate aggregators, entities that negotiate lower prices with drug companies. But these negotiations have a downside: They can obscure the details of drug company rebates, especially since most of the aggregators are owned by the same insurance conglomerates that own the big PBMs. Potential disruption: Changing PBMs means employees must adjust to a new formulary, pharmacy network, and prior authorization procedures. Members may also object to the stricter utilization controls these companies use. Buying power: Smaller PBMs do not have the volume that the larger players do and are also unable to take on the risk of aggressive discount and rebate guarantees which can lead to a financial arrangement that appears to be less advantageous for employers. Renegotiating with your existing PBM Many companies that have investigated using a more transparent PBM ultimately decide that the advantages of sticking with a large provider outweigh the frustrations and potential conflicts. They are: Convenience: Dealing with one company that provides medical benefits, pharmacy benefits, and mail-order pharmacy service can be easier for employers and plan members alike. Lower effective prices: Some employers find that the greater bargaining clout of the large PBMs delivers good value even if the mechanics of their arrangements remain murky. Increased transparency efforts: Faced with the prospect of increased regulation, CVS Caremark, Express Scripts, and OptumRX have all announced programs that disclose more information about pricing and pass more of their rebates to employers. As they are just being instituted, their real-world impact remains to be seen. In any case, employers and their advisors can't afford to wait to scrutinize their PBM's business practices and press for more advantageous contracts. The time is now to: Look at the fine print: A typical PBM contract may specify high-level drug discounts, rebates, and dispensing fees. Dig deeper, and you can find exclusions and key definitions, such as what is a 'specialty drug.' Press for full pass-through of rebates: Work through every category and proposed exception to insist that rebates for all drugs go to the employer. Ask about conflicts: How does the PBM interact with its affiliated pharmacies? Are reimbursements different than those for independent pharmacies? Are the dispensed drugs made by brands it owns? Check its approach to cost control: What is its philosophy for adding drugs to its formulary? How does it generate prior authorization guidelines for drugs with high rebates? What percent of authorization requests are approved? Audit performance: At the end of a contract, demand a detailed itemization of all claims to ensure that the PBM has met its commitments. If it hasn't, fight for a financial adjustment. Whether your company decides to find a new PBM or renegotiate its deal with the current provider, there are a lot of details to consider. An experienced broker or consultant will help you sort through those complex contracts designed to confuse. And if Washington does end up passing PBM reform, that advisor will also be able to adapt your plan to take maximum advantage of the new rules. To learn more, contact Chris Mast, an actuary and benefits consultant with Alliant Employee Benefits in Greenwood Village, CO. Mast has worked with employers across Colorado and the US for more than 20 years. He can be reached at Alliant's Pharmacy team is made up of industry experts, pharmacists, and data specialists who provide marketplace perspective and insights, vendor capabilities, and practical knowledge to secure the best pricing and contract arrangements. Our buying power and partnerships enable us to support your benefits strategy, pharmacy program, and cost management throughout the entire program lifecycle. Learn more about Alliant at
Newsweek
24-07-2025
- Newsweek
Health Care Data CEO Gets Real About Wearables
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox. Good morning. Moody's released its quarterly health care report on Tuesday. Let's take a look at the highlights. Moody's quarterly paints a sobering picture for hospitals and health systems. The biggest headline, unsurprisingly, is that Medicaid cuts are coming—and they're steep. The newly enacted federal budget reconciliation law is projected to slash Medicaid spending by $1.1 trillion through 2034, compared to previous projections from the Congressional Budget Office. This could leave hospitals with more uninsured patients and fewer reimbursement dollars, especially safety-net and rural providers. Congress' next moves will determine the exact conditions of this new normal. If lawmakers do not extend expanded premium tax credits for the Affordable Care Act by the end of the year, the CBO estimates that the number of uninsured Americans would increase by at least 4.2 million. Republicans are not keen on this measure, but it's still possible that they could compromise with Democrats to get other key GOP health care policies passed. One of those key policies is pharmacy benefit manager (PBM) reform, something that, historically, has garnered bipartisan support. They've been criticized by lawmakers on both sides of the aisle for overcharging for medications. Cigna, CVS Health and UnitedHealth—which together own 80 percent of the PBM market—face a credit risk if the government does crack down, according to Moody's. For more on the Congressional health care standoff, read on to the next section. Insurers' finances are also in a precarious position. On the bright side, CMS' Medicare Advantage reimbursement rate is rising to 5.1 percent in 2026. This is likely to float the industry to more typical earnings and margins after a period of weak performance, Moody's projects. But its analysts aren't sure how long it will take to regulate. For now, they gave health insurers a "negative" outlook due to higher-than-expected spending, particularly on weight-loss drugs and behavioral health care. I'll end on a positive note. Moody's analyzed CMS data, which suggests that the independent dispute resolution (IDR) process is becoming more efficient. The No Surprises Act (NSA) has been a headache for many providers since it was enacted in 2022, but the process is finally hitting its stride, per the numbers. New IDR claims continued to increase throughout 2024, but the number of resolved claims began to surpass new claims starting in the third quarter. "This, along with a consistently high provider win rate in disputes, suggests a decline in NSA-related accounts receivable and an easing of liquidity stress," Moody's analysts said in the report. How are you feeling about your organization's financial situation as we head into the latter half of 2025? Let me know at In Other News Major health care headlines from the week Congressional Republicans are hoping to pass a bipartisan health care package by year's end, with proposals to rein in pharmacy benefit managers (PBMs), expand Medicare coverage for weight-loss drugs and boost cancer screenings. But Democrats—frustrated by deep Medicaid cuts in the recent GOP megabill—are demanding Affordable Care Act tax credit extensions as a condition for talks, according to Politico. But Democrats—frustrated by deep Medicaid cuts in the recent GOP megabill—are demanding Affordable Care Act tax credit extensions as a condition for talks, according to Politico. The standoff highlights deep partisan tensions over health care, with both sides weighing how much they're willing to trade to secure their policy wins. Bankrupt hospital operator Steward Health Care has filed a lawsuit against its former CEO Ralph de la Torre and three other executives, alleging they harmed the company "through their greed and bad faith misconduct." and three other executives, alleging they harmed the company "through their greed and bad faith misconduct." A spokesperson for de la Torre told the Telegram & Gazette that he denies the allegations. Massachusetts-based Steward filed for bankruptcy in May 2024, subsequently closing two hospitals and selling others. De la Torre has previously been criticized for buying a megayacht while the system was in financial and legal turmoil. Hims & Hers is facing a lawsuit from a group of its shareholders , alleging the telehealth platform's senior executives and board gave misleading statements to investors. , alleging the telehealth platform's senior executives and board gave misleading statements to investors. The plaintiffs claim that Hims & Hers misrepresented its short-lived partnership with Novo Nordisk , which was announced in April and terminated by the pharmaceutical company in late June. Hims & Hers allegedly told investors that it could offer both Novo Nordisk's Wegovy and compounded semaglitude under the agreement—which Novo Nordisk has denied, calling the sale "deceptive" and claiming it "put patient safety at risk." , which was announced in April and terminated by the pharmaceutical company in late June. Hims & Hers allegedly told investors that it could offer both Novo Nordisk's Wegovy and compounded semaglitude under the agreement—which Novo Nordisk has denied, calling the sale "deceptive" and claiming it "put patient safety at risk." The investors' lawsuit also claims that Hims & Hers falsely represented the legality of compounded semaglutide sales, and told them it was compliant with FDA regulations. The Alice L. Walton School of Medicine has officially opened in Bentonville, Arkansas, TIME reported. Walton—Walmart heiress and the world's richest woman—will cover tuition for the first five graduating classes. Pulse Check Executive perspectives on key industry issues Jannine Versi is the CEO and co-founder of Elektra Health. Jannine Versi is the CEO and co-founder of Elektra Health. Elektra Health We're gearing up for our Women's Global Impact event on August 5 in New York City, and a number of health care leaders will be in attendance from companies like MUSC, the American Heart Association, Northwell Health and Virtua Health. During our health care spotlight panel, we'll discuss the leadership gender gap in the industry and explore how women executives are working to bring more attention to female health issues. For this week's Pulse Check, I'm bringing you a sneak peek from my interview with Jannine Versi, co-founder and CEO of Elektra Health. The company aims to "smash the menopause taboo" via its telehealth clinic, educational materials and private community for women. Here's what Versi told me about her journey and priorities: Has being a woman shaped your leadership style or the way that you think about your work in the health care industry? Absolutely. I know what it feels to be dismissed or minimized or told by a provider "that's just PMS" "or you need to manage your stress" in an offhanded way when something feels wrong. In terms of my team, we are female-founded and predominantly identify as women, but I actually don't think that changes how I try to lead — with urgency and empathy and also, with a high bar because our patients deserve the best. Women make up 70 percent of the global health care workforce, but hold just 25 percent of the industry's leadership positions. What do you make of this gender gap? How might we begin to close it? This gap is a moral issue and a missed opportunity. Women are the engine of the health care system, yet their perspectives are often missing from the rooms where decisions get made. That disconnect affects everything from research agendas to benefit design. We need more women at the helm of health systems, on investment committees and leading companies. But we also need systems that are built to retain and promote them. That means flexible leadership paths, accountability on gender metrics and real investment in women-led innovation. Put differently, I believe in the power of diversity, equity and inclusion. I also want to call out a couple partner organizations – like the University of Pittsburgh Medical Center (UPMC) and Emblem Health — both led by women — which aren't just talking about women's health. They're investing in it meaningfully because it's smart and strategic for their business and the right thing to do in serving patients and members. Meanwhile, I have heard for a long time from various payers and systems that they are "still figuring out" their women's health strategy. I suspect some will regret not moving more swiftly because women are increasingly and rightly expecting better from their providers and insurers. That kind of leadership sets a new standard—and hopefully, it's just the beginning. Register here to see Versi speak live at Newsweek's Women's Global Impact Summit in New York City on August 5. C-Suite Shuffles Where health care leaders are coming and going Bill Gassen has been chair-elect of the American Hospital Association. The Sanford Health CEO will assume the seat in 2027, making him the AHA's top elected official. has been named The Sanford Health CEO will assume the seat in 2027, making him the AHA's top elected official. Click here to snag a ticket! Gassen will be speaking at Newsweek's Digital Health Care Forum on September 16 in New York City. I'll be moderating the conversation, discussing the business case for technology and innovation. Howard University Hospital Corporation in Washington, D.C., has selected Kerry Watson as its interim CEO, effective August 1. This won't be his first time at the safety-net health system; he worked there as an administrator from 1982 to 1992. Watson has held numerous executive roles at health systems across the U.S., including service as interim CEO of UF Health St. Johns, CEO of Maui Health System and president of Wellstar Atlanta Medical Center (which shuttered in 2022). UC Davis Health has has announced three changes to its leadership team, selecting an interim CEO, interim vice chancellor of human health sciences and permanent dean of the School of Medicine. Dr. David Lubarsky, former CEO and vice chancellor of human health sciences, retired in February to become president and CEO of Westchester Medical Center Health Network in his home state of New York. to become president and CEO of Westchester Medical Center Health Network in his home state of New York. The California health system has divided his former positions amongst Michael Condrin (interim CEO) and Dr. Bruce Lee Hall (interim vice chancellor of human health sciences). Condrin most recently served as UC Davis Medical Center's chief operating officer, while Hall was the enterprise's chief clinical officer. (interim CEO) and (interim vice chancellor of human health sciences). Condrin most recently served as UC Davis Medical Center's chief operating officer, while Hall was the enterprise's chief clinical officer. Dr. Susan Murin assumed the top role at the School of Medicine in January, reporting to Hall. She has been with UC Davis Health for 29 years, previously as vice dean for clinical affairs and executive director of its medical group. Executive Edge How health care execs are managing their own health Dr. Mitesh Rao is the founder and CEO of OMNY Health. Dr. Mitesh Rao is the founder and CEO of OMNY Health. OMNY Health For this week's Executive Edge, I connected with Dr. Mitesh Rao, founder and CEO of the health care data platform OMNY Health. I've featured him before for his insights on wearable technology and how he uses it to monitor his health while balancing a busy work and travel schedule. In late June, at a House Energy Committee hearing, HHS Secretary Robert F. Kennedy Jr., told lawmakers that wearables will be "key" to his "Make America Healthy Again" (or "MAHA") agenda. He hopes that every American will be wearing one of these devices in the next four years—a goal that sparked significant debate about wearables' data security and efficacy. I followed up with Rao to get his latest take on wearable tech in health care. Here's what he told me: "Wearables have become a hot topic in health care, especially after RFK Jr. touted plans to get every American wearing one, then quickly backed off. I wear an Oura ring daily and have tried a variety of different wearables, including a Fitbit and a Google Watch, which I found more distracting than helpful." "What keeps me coming back to wearables isn't the reminders to stand up or go for a walk--it's the data. I enjoy seeing how my sleep quality changes after a long week of work travel, or how my body responds to things like a late dinner or a skipped workout. These are helpful personal reminders and insights, but it doesn't necessarily mean I will eat dinner earlier tomorrow or skip my next work trip." These are helpful personal reminders and insights, but it doesn't necessarily mean I will eat dinner earlier tomorrow or skip my next work trip." "That said, I do see value in wearable data in the clinical setting, and research shows 94 percent of people who use one are open to sharing their data with their doctor . However, as someone who has devoted their career to democratizing access to health care data, I believe we need to address some major privacy concerns before rushing to use these insights for research." . However, as someone who has devoted their career to democratizing access to health care data, I believe we need to address some major privacy concerns before rushing to use these insights for research." " Think about 23andMe . A few years ago, everyone was quick to take the saliva test, but when they filed for bankruptcy, people immediately realized 'Wait, my DNA could be sold in a fire sale?'" . A few years ago, everyone was quick to take the saliva test, but when they filed for bankruptcy, people immediately realized 'Wait, my DNA could be sold in a fire sale?'" "If wearable data is going to be used responsibly, we must always make sure it benefits people more than it benefits platforms. This begins with transparency. Every time I've set up a new wearable device for myself, I've chosen not to allow it to share my data for 'research' because I've no insight into how or what is being done with that data, or how it will be secured and protected. Until this is made clear for users, we're not ready to apply it meaningfully in health care." Before you go, check out Dr. Lawrence Rosenberg's reflection on what "excellence" actually means in health care. He is the president and CEO of the Integrated Health & Social Services University Network for West-Central Montreal, and a member of Newsweek's CEO Circle. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
